LFVN

LifeVantage Corporation

Price

$4.14

return (12m)

p/e

14.06

p/bv

2.43

DIVIDEND YIELD

2.97%

LFVN price

LifeVantage

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment LFVN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals LFVN

Valuation

P/E

14.06

Sector -4.15

Industry -4.15

P/BV

2.43

Sector 2.06

Industry 2.06

P/Revenue (PSR)

0.41

Sector -4.16

Industry -4.16

EV/EBITDA

28.61

Sector -241.86

Industry -241.86

EV/EBIT

40.70

Sector -671.75

Industry -671.75

P/EBITDA

8.59

Sector -4.30

Industry -4.30

P/EBIT

12.27

Sector -4.35

Industry -4.35

P/Total Assets

1.30

Sector 1.46

Industry 1.46

P/Net Current Assets

7.69

Sector -12.67

Industry -12.67

P/Working Capital

4.21

Sector -12.58

Industry -12.58

EPS

0.44

Sector -2.19

Industry -2.19

BVPS

2.56

Sector 1.92

Industry 1.92

Efficiency

Gross Margin

78.14%

Sector 36.44%

Industry 36.44%

EBITDA Margin

5.47%

Sector -16,748.51%

Industry -16,748.51%

EBIT Margin

3.84%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

3.37%

Sector -38.78%

Industry -38.78%

Net Profit Margins

2.94%

Sector -39.93%

Industry -39.93%

Asset Turnover

0.70

Sector 0.03

Industry 0.03

Profitability

ROE

17.25%

Sector -67.01%

Industry -67.01%

ROA

9.25%

Sector -66.28%

Industry -66.28%

ROIC

16.91%

Sector -2,917.75%

Industry -2,917.75%

Dividends

Dividend yield

2.97%

Sector -

Industry -

Payout

41.76%

Sector -

Industry -

Debt

Current Ratio

1.96

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-5.22

Sector -12,252,405.04

Industry -12,252,405.04

Net Debt / EBIT

-7.43

Sector -3.79

Industry -3.79

Net Debt / Equity

-0.37

Sector -33,290.93

Industry -33,290.93

Gross Debt / Equity

0.00

Sector 0.00

Industry 0.00

Equity/Assets

0.54

Sector 0.42

Industry 0.42

Liabilities/Assets

0.46

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-1.60%

Sector -

Industry -

5Y Earnings CAGR

-10.53%

Sector -

Industry -

FAIR VALUE OF LifeVantage ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$4.14

Fair Value

$5.03

Upside Return potential.

21.75%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals LFVN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
LFVN LifeVantage Corporation	$4.14	-70.06%	2.97%	14.06	2.43	17.25%	2.94%
AZN AstraZeneca PLC	$204.64	53.45%	1.89%	25.20	5.52	21.93%	17.19%
JNJ Johnson & Johnson	$240.16	62.69%	2.08%	28.83	0.00	-%	21.48%
NBIX Neurocrine Biosciences Inc.	$130.81	43.95%	0.00%	25.46	5.00	19.62%	21.55%
ABEO Abeona Therapeutics Inc.	$5.19	12.83%	0.00%	6.09	2.78	45.63%	100.00%
PFE Pfizer Inc.	$27.11	32.71%	6.97%	18.76	1.55	8.29%	11.83%
ABBV AbbVie Inc.	$210.26	25.08%	2.61%	125.53	-69.01	-54.98%	5.79%
ABUS Arbutus Biopharma Corporation	$4.35	38.54%	0.00%	5.66	3.50	61.77%	83.94%
ACAD ACADIA Pharmaceuticals Inc.	$22.02	51.03%	0.00%	11.55	3.48	30.10%	34.30%
ADMA ADMA Biologics Inc.	$10.49	-45.93%	0.00%	12.58	5.33	42.37%	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

LFVN Historical Dividends

current DY: 2.97%

5-year average DY: 3.72%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	03/02/2026	03/16/2026	0.04500000
Dividends	12/01/2025	12/15/2025	0.04500000
Dividends	09/08/2025	09/16/2025	0.04500000
Dividends	05/30/2025	06/13/2025	0.04500000
Dividends	03/03/2025	03/17/2025	0.04000000
Dividends	12/02/2024	12/16/2024	0.04000000
Dividends	09/09/2024	09/17/2024	0.04000000
Dividends	05/31/2024	06/14/2024	0.04000000
Dividends	03/01/2024	03/15/2024	0.03500000
Dividends	12/01/2023	12/15/2023	0.03500000
Dividends	09/08/2023	09/22/2023	0.43500000
Dividends	06/01/2023	06/15/2023	0.03500000
Dividends	03/01/2023	03/15/2023	0.03000000
Dividends	12/01/2022	12/15/2022	0.03000000
Dividends	09/02/2022	09/15/2022	0.03000000
Dividends	05/17/2022	05/31/2022	0.03000000

ABOUT LifeVantage

LifeVantage Corporation

Average Investor10 user rating

4.0 (0 people)

States of America

38 years

Founded: 1988

1997

Time since IPO - 29 years

247

Employees

LifeVantage Corporation (States of America) is listed on the Nasdaq and has a market capitalization of $80.86 million, with shareholders equity totaling $33.34 million.

The company employs approximately 247 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, LifeVantage Corporation reported $195.32 million in revenue, generating net income of $5.75 million.

Key financial metrics include a P/E ratio of 14.06, a price-to-book (P/B) ratio of 2.43, and a trailing twelve-month dividend yield of 2.97%.

The company trades under the ticker LFVN.

Market cap

$80.86 million

Net worth

$33.34 million

$33,340,000.00

Assets

$62.13 million

$62,130,000.00

Total Shares Outstanding

13.00 million

13,000,000

Average Daily Trading Volume

$532.90 Thousand

$532,898.00

Sector

Healthcare

Industry

Biotecnologia

LFVN

LFVN revenue and profits

Financial Results LFVN

DRAG THE FRAME TO SEE MORE DATA

LFVN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 22,54% (12M)

P/E

21.66

0.39%

ROE

-570.98%

P/BV

-123.68

CAH - Cardinal Health

$214.95 38,63% (12M)

P/E

34.90

0.89%

ROE

-58.20%

P/BV

-20.31

JNJ - Johnson & Johnson

$240.16 47,25% (12M)

P/E

28.83

2.08%

ROE

P/BV

0.00

MRK - Merck & Co.

$119.96 46,43% (12M)

P/E

35.53

2.62%

ROE

19.45%

P/BV

6.91

AZN - AstraZeneca

$204.64 40,78% (12M)

P/E

25.20

1.89%

ROE

21.93%

P/BV

5.52

ABBV - AbbVie

$210.26 15,08% (12M)

P/E

125.53

2.61%

ROE

-54.98%

P/BV

-69.01

NVO - Novo Nordisk

$39.32 --40,26% (12M)

P/E

11.83

3.68%

ROE

60.40%

P/BV

7.14